Progyny, Inc. (PGNY) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Progyny, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Progyny is a global leader in women's health and family building solutions, specializing in fertility benefits, pharmacy benefits (Progyny Rx), and expanded offerings including pregnancy, postpartum, menopause, and parent/child wellbeing. The company operates a "Smart Cycle" bundled treatment model and manages a selective network of over 1,100 fertility specialists across 690+ clinic locations.
Client Base: As of December 31, 2025, Progyny served 555 employer clients covering approximately 6.7 million members (up from 473 clients and 6.5 million members in 2024).
Key Financial Metrics
| Metric (in thousands, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $1,288,661 | $1,167,221 | +10.4% |
| Cost of Services | $984,177 | $913,858 | +7.7% |
| Gross Profit | $304,484 | $253,363 | +20.2% |
| Gross Margin | 23.6% | 21.7% | +190 bps |
| Operating Income | $85,277 | $67,455 | +26.4% |
| Net Income | $58,520 | $54,336 | +7.7% |
| Diluted EPS | $0.65 | $0.57 | +14.0% |
| Adjusted EBITDA | $222,092 | $198,760 | +11.7% |
| Cash & Cash Equivalents | $112,238 | $162,314 | -30.9% |
| Marketable Securities | $197,858 | $65,640 | +201.4% |
| Total Debt | $0 | $0 | N/A |
Note: The company has a $200 million revolving credit facility established in July 2025, but no amounts were drawn as of December 31, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 14% increase in fertility benefits revenue and a 5% increase in Progyny Rx revenue, primarily due to an expanded client base and covered lives.
- Margin Expansion: Gross margin improved by 190 basis points to 23.6%, attributed to efficiencies in care management service delivery.
- Expense Increases: General and Administrative (G&A) expenses rose 21% to $147.1 million. This included a $5.0 million increase in stock-based compensation (partially due to $7.7 million in executive severance costs) and a $4.1 million increase in bad debt expense.
- Client Concentration: In 2024, one client accounted for 12% of revenue; this client terminated its agreement effective January 1, 2025. In 2025, no single client accounted for more than 10% of total revenue.
- Acquisitions: Completed the acquisition of Benefit Bump LLC (parental leave navigation) in January 2025 for $10.5 million and Apryl GmbH (global fertility platform) in June 2024.
Guidance, Outlook, and Risks
- Guidance: On February 26, 2026, the company issued guidance for Q1 2026 and full-year 2026 (specific numerical targets not detailed in this text summary).
- Share Repurchases: In November 2025, the Board authorized a new $200 million share repurchase program. As of the filing date, the company had repurchased approximately 6.5 million shares for $159.4 million under this program.
- Strategic Outlook: Management expects continued growth through client acquisition, expansion of Progyny Rx adoption (92% of current clients utilize it), and penetration of new solutions (pregnancy, menopause, etc.).
- Key Risks:
- Regulatory Environment: Significant exposure to evolving laws regarding reproductive rights, PBM regulation (including the Consolidated Appropriations Act of 2026 requiring rebate pass-throughs), and data privacy (HIPAA, CCPA).
- Client Concentration & Retention: Dependence on large self-insured employers, particularly in the technology sector, and the risk of client churn or renegotiation.
- Cybersecurity: Reliance on IT systems and third-party vendors creates risks of data breaches and service disruptions.
- Utilization Volatility: Revenue is highly dependent on member utilization rates, which can fluctuate based on economic conditions and member demographics.
Investor Verification Checklist
- Client Retention: Verify the impact of the 2024 large client departure on 2025 revenue stability and the success of replacing that volume with new clients.
- Utilization Rates: Monitor the "Utilization - All Members" metric (1.32% in 2025 vs 1.31% in 2024) to ensure growth is driven by volume rather than just price increases or one-time spikes.
- Regulatory Impact on Margins: Assess the potential financial impact of the new 2026 PBM reforms requiring 100% rebate pass-throughs on Progyny Rx margins.
- Stock-Based Compensation: Review the $131.9 million SBC expense and the specific $7.7 million executive severance charge to understand the trajectory of future non-cash expenses.
- Cash Flow Management: Confirm that the shift from cash equivalents to marketable securities ($197.9M) aligns with liquidity needs given the seasonal nature of revenue collection.